

PORTUGAL

Recent and planned developments in pharmaceutical policies 2014

Policies related to high cost medicines

D E V E L O P M E N T S	<p style="text-align: center;">Changes in pricing</p> <ul style="list-style-type: none"> • Annual price review: non-generics; and hospital medicines not previously assessed and with sales above 1M€ (01/2014) • Margin changes: new values for fixed and percentage wholesale and pharmacy margins, which vary by price ranges (04/2014) • International reference pricing: countries changed from Spain, France and Slovakia to Spain, France and Slovenia (01/2014) and will be maintained in 2015 (11/2014) 	<p style="text-align: center;">Changes in reimbursement</p> <ul style="list-style-type: none"> • Changes/modifications of reimbursement lists: delist of some pharmacotherapeutic groups and inclusion of new reimbursable groups (03/2014) • Reimbursement reviews: update of the criteria for the reimbursement assessment and review; introduction of the review of reimbursement whenever there's a change in the therapeutic indications (04/2014) • Other changes/modifications of the reimbursement system: for generics it is established a price threshold not lower than 20% of the medicine of reference price (04/2014)
	<p style="text-align: center;">Other changes</p> <p>SiNATS - National System for Health Technology Assessment (under implementation):</p> <ul style="list-style-type: none"> - Technology: Medicines + Medical Devices + (...) - Assessment: <ol style="list-style-type: none"> Relative Effectiveness (Added Therapeutic Value) Cost-Effectiveness (Economic Value) Other dimensions of the technology value (including affordability) - Decisions: <ol style="list-style-type: none"> Price Financing/reimbursement Control and cost limitation Risk sharing Additional monitoring of use <p>-Re-assessment of technologies on the market (ex-post evaluation) – New paradigm</p>	
S P E C I A L T O P I C	<p style="text-align: center;">High cost medicines</p> <ul style="list-style-type: none"> • <u>Special pricing policies:</u> There are no specific pricing policies for high cost medicines. • <u>Special reimbursement/funding policies:</u> There are no reimbursement/funding policies for high cost medicines. • <u>High cost medicines at the interface of out-patient and in-patient sectors:</u> Outpatient sector: reimbursed medicines are financed by NHS Inpatient sector: medicines are funded via DRG system; Comprehensive Price or Special reimbursed schemes for medicines dispensed in hospital pharmacy setting • <u>Key challenges and solutions:</u> New high cost medicines with a great impact in the NHS budget (e.g. Hepatitis C): monitoring of patient registries and risk sharing agreements 	